- Home
- NCPL vs ALLR Comparison
NCPL vs ALLR Comparison
Compare NCPL & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- ALLR
- Stock Information
- Founded
- NCPL 1984
- ALLR 2004
- Country
- NCPL United States
- ALLR United States
- Employees
- NCPL N/A
- ALLR N/A
- Industry
- NCPL Investment Managers
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- ALLR Health Care
- Exchange
- NCPL Nasdaq
- ALLR Nasdaq
- Market Cap
- NCPL 4.3M
- ALLR 4.0M
- IPO Year
- NCPL N/A
- ALLR N/A
- Fundamental
- Price
- NCPL $2.67
- ALLR $0.87
- Analyst Decision
- NCPL
- ALLR
- Analyst Count
- NCPL 0
- ALLR 0
- Target Price
- NCPL N/A
- ALLR N/A
- AVG Volume (30 Days)
- NCPL 153.1K
- ALLR 660.5K
- Earning Date
- NCPL 07-28-2025
- ALLR 05-09-2025
- Dividend Yield
- NCPL N/A
- ALLR N/A
- EPS Growth
- NCPL N/A
- ALLR N/A
- EPS
- NCPL N/A
- ALLR N/A
- Revenue
- NCPL $812,612.00
- ALLR N/A
- Revenue This Year
- NCPL N/A
- ALLR N/A
- Revenue Next Year
- NCPL $101.16
- ALLR N/A
- P/E Ratio
- NCPL N/A
- ALLR N/A
- Revenue Growth
- NCPL N/A
- ALLR N/A
- 52 Week Low
- NCPL $1.41
- ALLR $0.61
- 52 Week High
- NCPL $11.90
- ALLR $20.44
- Technical
- Relative Strength Index (RSI)
- NCPL 75.93
- ALLR 36.97
- Support Level
- NCPL $1.75
- ALLR $1.02
- Resistance Level
- NCPL $2.19
- ALLR $1.06
- Average True Range (ATR)
- NCPL 0.18
- ALLR 0.08
- MACD
- NCPL 0.04
- ALLR -0.03
- Stochastic Oscillator
- NCPL 89.01
- ALLR 12.56
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.